Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Prasugrel better on stent-related clots than Plavix: study
- CHICAGO, March 29, 2008 AFP — A cocktail of new anti-blood clot drug Prasugrel and aspirin reduces the risk of stent-related clots more than the standard treatment, according to a clinical trial review presented Saturday. Prasugrel cut the risk of platelet formation around where a stent -- a small...
- Research articles 2008-03-29
- Moody's Cuts Lilly's Debt Rating; Daiichi Says It's Confident in Prasugrel
- Moody's, the debt rating service, cut its rating of the quality of Eli Lilly's credit down to A1 from Aa3. The move indicates that Lilly's acquisition of ImClone has come with a price on top of the one on the sales tag. Moody's said: Although the ImClone acquisition creates...
- Blog posts 2008-11-23
- Pharma Roundup: Lilly and Prasugrel, Roche and Genentech, and More
- Prasugrel's FDA approval looks closer -- Prasugrel, the blood thinner on which Lilly is pinning so much hope, got a boost in a newly-published FDA document stating that "the Division recommends approval of prasugrel." The briefing is meant to sway the outside committee that will convene next week to advise...
- Blog posts 2009-01-30
Additional Resources
- FDA's Prasugrel Machinations Seem Bound to Attract Doubt
- UPDATE: Dr. Sanjay Kaul was bounced from the FDA's prasugrel panel after Eli Lilly called the FDA to question his inclusion on the panel, according to HeartWire. The FDA has admitted it made a "mistake" by axing Kaul. "At every step of the way there were errors by multiple parties,"...
- Blog posts 2009-02-23
- More Bad News for Lilly's Prasugrel
- The bleeding risks of Eli Lilly's new blood thinner, prasugrel, are less clear than the company thinks, according to a Cedars Sinai cardiologist. The drug -- which Lilly hopes will be huge -- is currently under review by the FDA but has suffered a series of delays that have set...
- Blog posts 2008-11-11
- Odds Improve for Lilly's Prasugrel-ImClone Gamble
- A panel of the European Medicines Agency recommended the approval of prasugrel, Eli Lilly's new blood thinner, and such recommendations are usually followed by the agency within a couple of months, Reuters reports. The news is a significant win in Lilly's long campaign to get this drug to market. It...
- Blog posts 2008-12-19
- In Light of Prasugrel Delay, Lilly-ImClone Deal Suddenly Makes Sense
- For those of you wondering why Eli Lilly would volunteer to have its stock crushed by the loss of cash and added debt required to buy ImClone, here's one idea: The deal makes more sense if Lilly believes that prasugrel -- a potential blockbuster blood thinner with the brand name...
- Blog posts 2008-10-17
- Lilly CEO Lechleiter's Prasugrel Bet Appears to Pay Off
- A few months ago, BNET suggested that Eli Lilly's acquisition of ImClone was a hedge to give the company new revenue sources in the event that its application for blood thinner prasugrel was turned down by the FDA. An FDA panel today voted 9-0 to approve the...
- Blog posts 2009-02-03
- Pharma Roundup: Prasugrel Delays Fit FDA Trend; Pfizer Settles Celebrex Suits; and More
- Lilly's Prasugrel not alone in FDA delays; Pfizer paying $894 million in Celebrex suits; Wikipedia #1 drug information source in Europe; Teva teaching about generic biologics through online game. by John Maas
- Blog posts 2008-10-17
- Pharma Roundup: Lilly's Prasugrel in Europe, AstraZeneca's $900 Million Deal, and More
- EMEA backs Lilly's prasugrel, AZ pays $900 million for MAP partnership, Targanta lays off 85, Vertex's new hepatitis C drug may fetch $75,000. by John Maas
- Blog posts 2008-12-19
- Pharma Roundup: Pfizer's Acquisition Plans, Prasugrel's Big Day, and More
- Pfizer wants acquisitions, big and small. Prasugrel has a date with the FDA. New Year's blog feature bonanza. Farewell, Pharmalot. by John Maas
- Blog posts 2009-01-05
- Prasugrel Doc Urges FDA to Nix Approval for Lilly Drug
- Just when Eli Lilly CEO John Lechleiter thought he was out of the woods on prasugrel/Effient -- he got a unanimous approval vote from an FDA panel in February -- comes a letter to the FDA from the guy who invented the drug that says it causes bleeding and cancer....
- Blog posts 2009-06-04
- In Landmark Phase III Head-to-Head Study, Prasugrel Statistically Superior to Clopidogrel in Reducing Risk of Heart Attack.
- TOKYO and INDIANAPOLIS, November 4 /PRNewswire/ -- - Investigational compound reduces risk of major cardiovascular events by 19 percent, significantly improves net clinical benefit despite increased bleeding In the pivotal Phase III head-to-head TRITON TIMI-38 clinical trial, the investigational antiplatelet agent...
- Research articles 2007-11-04
- LILLY (ELI) & COMPANY - In Phase III Study Prasugrel Superior to Clopidogrel.
- Date: November 4, 2007 Refer to: Joedy Isert Eli Lilly and Company 317-276-5592 office 317-997-8544 cell Jo-ann Straat Daiichi Sankyo USA 973-359-2602 office Shigemichi Kondo ...
- Research articles 2007-11-05
- Accumetrics' VerifyNow® P2Y12 Test Provides Physicians With Information to Assess a Patient's Response to Newly-Approved Prasugrel
- SAN DIEGO, July 14 /PRNewswire/ -- With the recent FDA approval of the new P2Y12 inhibitor, prasugrel Effient, Accumetrics, Inc. announces that its VerifyNow P2Y12 Test is not only able to assess response to Plavix , but also its newly approved competitor, Effient. In obtaining a result...
- Research articles 2009-07-14
- Pharma Roundup: Pfizer's Acquisition Plans, Prasugrel's Big Day, and More
- Pfizer CEO seeks big acquisition — In a much-discussed comment to the Financial Times, Pfizer's CEO Jeff Kindler revealed his aspirations for revenue-boosting deals, large and small. As the Health Blog points out, the takeaway here is Kindler's apparent willingness to pursue old-fashioned big acquisitions, at a time when most...
- News items 2009-08-07
- Lilly Advertises "Effient" Despite Lack of FDA Approval
- Eli Lilly is advertising its new blood-thinner, Effient, even though it is not yet approved in the U.S. The drug also known as prasugrel is approved in Europe as "Efient," but ads in which the drug's name is spelled with two f's have appeared on the cardiologytoday.com web site. "Effient"...
- Blog posts 2009-02-25
- Eli Lilly Q2 2007 Earnings Call Transcript
- Question-and-Answer SessionOperator Operator Instructions And our first question comes from the line of James Kelly of Goldman Sachs. Please go ahead. James Kelly - Goldman Sachs Thank you and good morning. My question relates to Zyprexa and the depot formulation, and thank you for the additional data in Canada...
- Earnings calls 2007-07-24
- Lilly Q1: Price Rises, End of Zyprexa Woes Boost the Numbers
- With its costly Zyprexa settlements out of the way, Eli Lilly got back to business as usual: Raising drug prices. And it seems to have paid off. Lilly's Q1 revenue was $5 billion, up from $4.8 billion the year before (but down sequentially from mid-2008 when quarterly revenues touched $5.2...
- Blog posts 2009-04-20
- FDA to review Lilly and Daiichi's anticlotting drug
- Prasugrel is an investigational antiplatelet agent for the treatment of patients with acute coronary syndromes who are being managed with an artery-opening procedure known as percutaneous coronary intervention, which is usually followed by the placement of a stent to help keep the artery open. Advisory committees provide the FDA with...
- News items 2009-08-07
- << Previous
- page 1 of 1
- Next >>
